Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

Directly switching from Hemlibra to Mim8 was well tolerated in people with hemophilia A, with or without inhibitors, a study ...

Mim8 (denecimig) prophylaxis was well-tolerated in FRONTIER5 phase 3 switch trial in people with haemophilia A ·         New FRONTIER5 data shows direct switch to Mim8 prophylaxis treatment from ...

Sterotherapeutics LLC, a clinical-stage biopharmaceutical company focused on rare endocrine diseases, today announced that the first patient has been successfully dosed in its ongoing ...

Novo Nordisk NVO announced new data from the phase III FRONTIER clinical program, comprising five separate studies evaluating ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

Indiana’s Tyrese Haliburton, who was playing with a strained right calf, went down with a lower right leg injury in the first ...

New phase 3 data will be presented on Mim8, an investigational mimetic therapy designed to replicate the function of missing clotting factors. 1 Analysis from the phase 3 FRONTIER5 trial will ...

A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood . 2021;138(14):1258-1268. MedlinePlus.